Company Overview
Company Type: Public Company
Website: www.tevapharm.com
Number of Employees: 34,565
Ticker: TEVA (NYSE)
Year Founded: 1901


Business Description
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company’s products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration with MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia, as well as a collaboration with Sanofi to co-develop and co-commercialize TEV-48574 asset, a novel anti-TL1A therapy for the treatment of ulcerative colitis and Crohn’s disease. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Financial Information (Currency: CAD, in mm) 
Total Revenue
20,462.9
Market Capitalization
14,384.8
TEV/Total Revenue
2.0x
EBITDA
5,058.2
Total Enterprise Value
40,279.3
TEV/EBITDA
7.6x
EBIT
3,380.7
Cash & ST Invst.
3,636.9
P/Diluted EPS Before Extra
NM
Net Income
(3,044.2)
Total Debt
28,637.5
Price/Tang BV
NM
Capital Expenditure
(711.3)
Total Assets
58,723.4
Total Debt/EBITDA
5.4x
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023


Estimates & Guidance Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Guidance Current FQ
Current FY
Guidance Current FY
NTM
EPS Normalized
0.85
-
3.11
3.07 - 3.47
3.33
Revenue (mm)
5,114.25
-
20,700.50
20,439.75 - 20,984.81
20,527.75
EBITDA (mm)
1,647.40
-
6,176.50
6,131.93 - 6,676.99
6,310.70

Forward Multiples (Current FY)

Price/Earnings
3.87x
TEV/REV
1.90x
TEV/EBITDA
6.37x
PEG
0.38x
P/BV
1.11x

Non-Periodic Estimates

Recommendation
Hold (2.54)
Target Price
14.92
Potential Upside
24.15%
LT Growth (%)
10.20%


Key Professionals
Name
Title
Francis, Richard D.
President, CEO & Director
Kalif, Eliyahu Sharon
Executive VP & CFO
Drape, Eric 
Executive Vice President of Global Operations
Weiss, Amir 
Senior VP & Chief Accounting Officer
Meir, Ran 
Head of Investor Relations
Stark, David M.
Executive VP & Chief Legal Officer
Veit, Kathleen 
Senior Vice President, Global Compliance & Ethics Officer
Inbar, Galia 
Executive VP, Chief Human Resources Officer & Corporate Affairs
Baron, Nir 
Senior VP & Chief Internal Auditor
Daniell, Richard Gordon
Executive Vice President of European Commercial
Dethlefs, Sven 
Executive Vice President of North America Commercial
Grant, Angus J.
Executive Vice President of Business Development

Key Board Members
Name
Title
Barer, Sol J.
Independent Chairman of the Board
Francis, Richard D.
President, CEO & Director
Crane, Rosemary A.
Independent Director
Elstein, Amir 
Independent Director
Lieberman, Gerald M.
Independent Director
Mignone, Roberto Agostino
Independent Director
Vergis, Janet S.
Independent Director
Braverman-Blumenstyk, Michal 
Nominee Independent Director
Nisen, Perry D.
Independent Director
Satchi-Fainaro, Ronit 
Independent Director
Shalev, Varda 
Independent Director
Zaks, Tal 
Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
124 Dvora Hanevi’a Street | Tel Aviv | 6944020 | Israel
Phone: 972 3 914 8213   

Current and Pending Investors
Capital Research and Management Company, Capital Research Global Investors, Clal Biotechnology Industries Ltd. (TASE:CBI), Fidelity Management & Research Company LLC, Soros Fund Management LLC

Prior Investors
AXA Financial, Inc.

Investment Arms
Teva Innovative Ventures (Prior), Teva Pharmaceutical Industries Ltd., Asset Management Arm

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 12.02
Market Cap (mm)
13,468.6
Open
 12.40
Shares Out. (mm)
1,120.7
Previous Close
 12.02
Float %
99.5%
Change on Day
(0.82)
Shares Sold Short (mm)
16.9
Change % on Day
(6.4)%
Dividend Yield %
-
Day High/Low
 12.57/ 11.98
Diluted EPS Excl. Extra Items
(2.74)
52 wk High/Low
 15.60/ 9.65
P/Diluted EPS Before Extra
NM
Volume (mm)
16.93
Avg 3M Dly Vlm (mm)
9.55
Beta 5Y
1.15


 
Delayed Quote** | Last Updated on Oct-09-2023 12:00 AM (GMT-5)
NYSE:TEVA - Depositary Receipt (Common Stock)


Index Membership
S&P Developed BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific LargeMidCap Value Index;S&P Developed BMI Value Index;S&P Developed Ex-Asia-Pacific BMI Value Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Europe BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe LargeMidCap Index;S&P DM Ex-Europe LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed BMI Index;S&P Developed Ex-Australia BMI Index;S&P Developed Ex-Australia LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific BMI Index;S&P DM Ex-Asia-Pacific BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific BMI Value Index;S&P Developed Ex-Australia LargeMidCap Index;S&P Developed Ex-Australia LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Canada BMI Index;S&P Developed Ex-Canada BMI Health Care (Sector) Index;S&P Developed Ex-Canada BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland BMI Index;S&P Developed Ex-Switzerland LargeMidCap Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.K. LargeMidCap Health Care (Sector) Index;S&P DM Ex-U.K. LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Eurozone BMI Index;S&P Developed Ex-Eurozone LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Eurozone LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Eurozone LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Japan BMI Index;S&P Developed Ex-Japan BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific LargeMidCap Index;S&P Developed Ex-Asia-Pacific LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Australia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia LargeMidCap Value Index;S&P Developed Ex-Switzerland BMI Health Care (Sector) Index;S&P Developed Ex-Switzerland LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia BMI Health Care (Sector) Index;S&P DM Ex-Canada LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P DM Ex-U.S. & Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland LargeMidCap Index;S&P Developed Ex-U.K. BMI Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan LargeMidCap Index;S&P Developed Ex-U.S. & Japan LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-U.S. & Japan LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Europe LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Europe LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Value Health Care (Sector) Index;S&P Developed Ex-U.S. & U.K. LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-U.S. & U.K. BMI Index;S&P Developed Ex-U.S. & U.K. LargeMidCap Index;S&P EPAC Ex-Japan LargeMidCap Value Index;S&P EPAC BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P EPAC Ex-Japan BMI Index;S&P Developed Ex-Eurozone LargeMidCap Value Index;S&P Developed Ex-Eurozone Over USD5 Billion Index;S&P Developed Ex-Switzerland LargeMidCap Value Index;S&P Developed Ex-Canada BMI Value Health Care (Sector) Index;S&P Developed Ex-Europe BMI Index;S&P Developed Ex-U.K. BMI Value Health Care (Sector) Index;S&P Developed Ex-U.K. LargeMidCap Index;S&P Developed Ex-U.K. Over USD5 Billion Index;S&P Developed Ex-U.S. & Japan BMI Index;S&P Developed Ex-U.S. & Japan BMI Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Value Index;S&P Developed Ex-U.K. LargeMidCap Value Index;S&P Developed BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Over USD5 Billion Index;S&P Developed Ex-Australia BMI Value Health Care (Sector) Index;S&P Developed Ex-Europe Over USD5 Billion Index;S&P Developed Ex-Japan BMI Value Health Care (Sector) Index;S&P Developed Ex-Japan LargeMidCap Index;S&P Europe, Mid-East & Africa BMI Index;S&P Europe, Mid-East & Africa BMI Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan BMI Value Index;S&P Developed Ex-U.S. & U.K. LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-U.S. BMI Value Health Care (Sector) Index;S&P Developed Ex-U.S. LargeMidCap Health Care (Sector) Index;S&P DM Ex-U.S. & U.K. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. BMI Index;S&P Developed Ex-U.S. BMI Health Care (Sector) Index;S&P DM Ex-U.S. LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia Over USD5 Billion Index;S&P Developed Ex-Canada LargeMidCap Index;S&P Developed Ex-Canada LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Canada Over USD5 Billion Index;S&P Developed Over USD5 Billion Index;S&P Global BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia BMI Value Index;S&P EPAC Ex-Japan BMI Value Index;S&P EPAC Ex-Japan BMI Value Health Care (Sector) Index;S&P EPAC Ex-Japan Over USD5 Billion Index;S&P Developed Ex-Europe BMI Value Index;S&P Developed Ex-Eurozone BMI Value Index;S&P Developed Ex-Eurozone LargeMidCap Index;S&P Developed Ex-Japan LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Japan LargeMidCap Value Index;S&P DM Ex-Switzerland BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland BMI Value Index;S&P Developed Ex-Switzerland LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Global Ex-U.S. BMI Health Care (Sector) Index;S&P Developed Ex-U.S. LargeMidCap Value Health Care (Sector) Index;S&P Developed LargeMidCap Index;S&P Developed LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland Over USD5 Billion Index;S&P EPAC BMI Value Index;S&P EPAC Ex-Japan LargeMidCap Health Care (Sector) Index;S&P Israel BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Israel LargeMidCap Value Index;S&P EPAC LargeMidCap Index;S&P EPAC Over USD5 Billion Index;S&P Developed Ex-U.S. & U.K. LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Australia BMI Value Index;S&P Europe, Mid-East & Africa Over USD5 Billion Index;S&P Developed Ex-U.S. & Japan BMI Value Health Care (Sector) Index;S&P Europe, Mid-East & Africa LargeMidCap Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan LargeMidCap Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan LargeMidCap Value Index;S&P Developed Ex-U.S. & U.K. BMI Health Care (Sector) Index;S&P Developed Ex-U.S. & U.K. Over USD5 Billion Index;S&P Developed Ex-Canada BMI Value Index;S&P Developed Ex-Europe BMI Health Care (Sector) Index;S&P Developed Ex-Europe BMI Value Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Health Care (Sector) Index;S&P DM Ex-Japan LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan Over USD5 Billion Index;S&P Global Ex-Japan Over USD5 Billion Index;S&P Global Ex-Pan Asia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Europe, Mid-East & Africa LargeMidCap Value Index;S&P Developed Ex-U.K. BMI Index;S&P Global Ex-Japan BMI Value Index;S&P Global BMI Index;S&P Global Ex-Japan BMI Health Care (Sector) Index;S&P Global Ex-Japan LargeMidCap Index;S&P Global Ex-Japan LargeMidCap Value Index;S&P Global Ex-Pan Asia LargeMidCap Value Index;S&P Global Ex-Pan Asia Over USD5 Billion Index;S&P Global Ex-U.S. BMI Value Index;S&P Global Ex-U.S. LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. BMI Value Index;S&P EPAC BMI Index;S&P EPAC Ex-Japan BMI Health Care (Sector) Index;S&P Israel LargeMidCap Health Care (Sector) Index;S&P EPAC BMI Health Care (Sector) Index;S&P Europe, ME & Africa BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Europe, Mid-East & Africa LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P EPAC BMI Value Health Care (Sector) Index;S&P EPAC Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P EPAC LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Europe, Mid-East & Africa BMI Value Index;S&P Global Ex-Pan Asia LargeMidCap Health Care (Sector) Index;S&P Global Ex-U.S. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. LargeMidCap Value Index;S&P Global Over USD5 Billion Index;S&P Israel BMI Health Care (Sector) Index;S&P Israel BMI Value Index;S&P Global Ex-Japan LargeMidCap Health Care (Sector) Index;S&P Global Ex-Japan LargeMidCap Pharmaceuticals, Biotech & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. BMI Index;S&P Global LargeMidCap Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan Over USD5 Billion Index;S&P Israel BMI Index;S&P Developed Ex-U.S. & U.K. LargeMidCap Value Index;S&P Developed Ex-U.S. LargeMidCap Index;S&P EPAC Ex-Japan LargeMidCap Index;S&P EPAC LargeMidCap Value Health Care (Sector) Index;S&P Global Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia BMI Index;S&P Global Ex-Pan Asia LargeMidCap Index;S&P Global Ex-Pan Asia LargeMidCap Pharmaceuticals, Biotech & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. LargeMidCap Index;S&P Global Ex-U.S. Over USD5 Billion Index;S&P Global LargeMidCap Index;S&P Global LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global LargeMidCap Value Index;S&P Israel LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Israel Over USD5 Billion Index;S&P Developed BMI Value Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific BMI Health Care (Sector) Index;S&P Developed Ex-Australia LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Canada LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Canada LargeMidCap Value Index;S&P Developed Ex-Europe LargeMidCap Value Index;S&P Developed Ex-Japan BMI Value Index;S&P Developed Ex-Japan LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Switzerland BMI Value Health Care (Sector) Index;S&P Developed Ex-U.K. LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-U.S. & U.K. BMI Value Index;S&P Developed Ex-U.S. & U.K. BMI Value Health Care (Sector) Index;S&P Developed Ex-U.S. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. LargeMidCap Value Index;S&P Developed Ex-U.S. Over USD5 Billion Index;S&P Developed LargeMidCap Health Care (Sector) Index;S&P Developed LargeMidCap Value Index;S&P Developed LargeMidCap Value Health Care (Sector) Index;S&P EPAC Ex-Japan LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P EPAC Ex-Japan LargeMidCap Value Health Care (Sector) Index;S&P EPAC LargeMidCap Health Care (Sector) Index;S&P EPAC LargeMidCap Value Index;S&P Europe, Mid-East & Africa LargeMidCap Index;S&P Global BMI Health Care (Sector) Index;S&P Global BMI Value Index;S&P Global Ex-Japan BMI Index;S&P Global Ex-U.S. LargeMidCap Health Care (Sector) Index;S&P Israel LargeMidCap Index;S&P Developed Ex-Eurozone BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. & Japan BMI Value Pharm, Biotech & Life Sciences (Industry Group) Index;S&P EPAC BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Asia Pacific BMI Value Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. & UK BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Switzerland BMI Value Pharm, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-UK BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Europe BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Canada BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P EPAC Ex-Japan BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Japan BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Mid-East & Africa Developed BMI Index;S&P Mid-East & Africa Developed BMI Health Care (Sector) Index;S&P Mid-East & Africa DM BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Israel BMI Value Health Care (Sector) Index;S&P Mid-East & Africa Developed BMI Value Index;S&P Mid-East & Africa Developed BMI Value Health Care (Sector) Index;S&P Mid-East & Africa Developed LargeMidCap Index;S&P Mid-East & Africa Developed LargeMidCap Health Care (Sector) Index;S&P Mid-East & Africa Developed LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Israel LargeMidCap Value Health Care (Sector) Index;S&P Mid-East & Africa Developed LargeMidCap Value Index;S&P Mid-East & Africa Developed LargeMidCap Value Health Care (Sector) Index;S&P Mid-East & Africa Developed Over USD5 Billion Index;S&P Global Ex-Australia BMI Index;S&P Global Ex-Europe BMI Index;S&P Global Ex-United Kingdom BMI Index;S&P Developed Ex-Continental Europe BMI Index;S&P Developed Ex-Japan, Ex-South Korea BMI Index;S&P Developed BMI Ex-U.S. & Korea LargeMidcap Index;S&P Developed BMI Ex-U.S. & Korea Index;S&P EPAC Ex-Korea BMI;S&P EPAC Ex-Korea LargeMidCap;S&P DM Ex. Japan LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global Ex-Australia LargeMidCap;S&P Israel LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Mid-East & Africa DM LargeMidCap Value Pharmaceuticals, Biotechnology & Life (Industry Group);S&P Developed Ex-Japan & South Korea LargeMidCap;S&P DM Ex-Canada LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P EPAC Ex-Japan LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P EPAC LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subsecto;S&P Developed Ex-Asia-Pacific LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subs;S&P Developed Ex-Australia LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Developed Ex-Switzerland LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subse;S&P DM Ex-Europe LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subs;S&P DM Ex-U.K. LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-U.S. LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & U.K. LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subse;S&P Mid-East & Africa DM BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Israel BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global Ex-Australia & New Zealand LargeMidCap;S&P Global Ex-China A BMI;S&P Global Ex-China A LargeMidCap;S&P Global Ex-U.S. & China A BMI;S&P Global Ex-U.S. & China A LargeMidCap;S&P Developed Ex-Korea BMI;S&P Global Ex-Japan & China A LargeMidCap;S&P Developed Ex-Korea LargeMidCap;S&P Developed BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific BMI Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Canada BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & UK BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & UK LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P EPAC BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK LargeMidCap Val Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Middle East & Africa BMI Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P EPAC Ex-Japan BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Canada LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland BMI Val Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan BMI Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Korea BMI Value;S&P Developed Ex-Korea LargeMidCap Value;S&P EPAC Ex-Korea BMI Value;S&P EPAC Ex-Korea LargeMidCap Value;S&P Developed Ex-Korea LargeMidCap Health Care (Sector) Index;"S&P Developed Ex-Korea LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Anda, Inc.
Anda, Inc. distributes generic, brand, specialty, and over-the-counter pharmaceutical (OTC) products. The company’s products include vaccines, injectables, medical/surgical supplies, OTCs/vitamins, and pet medications. The company helps to meet the needs of customers in long-term care pharmacies, managed care facilities, mail order pharmacies, physician offices, clinics, hospitals, and student health centers. It delivers customers’ orders by phone, fax, and through its website. It serves retail independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices in the United States. Anda, Inc. was formerly known as Anda Generics, Inc. and changed its name to Anda, Inc. in October 1999. The company was founded in 1992 and is based in Parsippany, New Jersey. As of October 3, 2016, Anda, Inc. operates as a subsidiary of Teva Pharmaceutical Industries Limited.

United States and Canada
Health Care Distributors
367.00
-
-
Representaciones e Investigaciones Medicas, S.A. de C.V.
As of March 3, 2016, Representaciones e Investigaciones Medicas, S.A. de C.V. was acquired by Teva Pharmaceutical Industries Limited. Representaciones e Investigaciones Medicas, S.A. de C.V. manufactures generic drug products. The company is based in Mexico City, Mexico. 

Latin America and Caribbean
Pharmaceuticals
194.00
-
-
Gecko Health Innovations, Inc.
As of September 30, 2015, Gecko Health Innovations, Inc. was acquired by Teva Pharmaceutical Industries Limited. Gecko Health Innovations, Inc. provides CareTRx, a cloud-based solution to simplify chronic respiratory disease management, and connect patients and caregivers through remote monitoring and real-time tools. It offers CareTRx Journal App, a solution to access the right information at the right time; CareTRx Sensor for Inhalers, which automatically tracks uses and gets scheduled dose reminders; CareTRx Population Monitoring Dashboard, which connects patients and care teams for disease management; and patient engagement, adherence, device to cloud, identify higher-risk patients, remote monitoring, payers and disease management, PBMs and pharma, CROs and research, and ACOs and IDNs solutions. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.

United States and Canada
Health Care Technology
-
-
-
Allergan plc, Global Generic Pharmaceuticals Business
As of August 2, 2016, Global Generic Pharmaceuticals Business of Allergan plc was acquired by Teva Pharmaceutical Industries Limited. Global Generic Pharmaceuticals Business of Allergan plc comprises generic drug assets. The asset is located in the United States.

United States and Canada
Pharmaceuticals
-
-
-
Auspex Pharmaceuticals, Inc.
Auspex Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops medicines for hyperkinetic movement disorders and other rare diseases. The company specializes in applying deuterium chemistry to known molecules to create novel therapies. Its portfolio includes Austedo (SD-809), a solution for the potential treatment of chorea associated with Huntington's disease, tardive dyskinesia, and Tourette syndrome; SD-560, a solution for fibrotic conditions; and SD-1077, a solution for Parkinson's disease. The company was founded in 2001 and is headquartered in San Diego, California. As of May 5, 2015, Auspex Pharmaceuticals, Inc. operates as a subsidiary of Teva Pharmaceutical Industries Limited.

United States and Canada
Biotechnology
-
151.00
15.00
Labrys Biologics, Inc.
As of July 17, 2014, Labrys Biologics, Inc. was acquired by Teva Pharmaceutical Industries Limited. Labrys Biologics, Inc., a development stage company operates as a biotechnology firm and develops antibody treatments for chronic migraines. The company was founded in 2012 and is based in San Francisco, California. 

United States and Canada
Biotechnology
-
-
-
NuPathe, Inc.
NuPathe Inc., a specialty pharmaceutical company, focuses on the development and commercialization of branded therapeutics for neurological and psychiatric disorders. The company’s lead product is Zecuity, which is a sumatriptan iontophoretic transdermal system used for the acute treatment of migraine with or without aura in adults. Its pipeline product candidates include NP201 for the continuous symptomatic treatment of Parkinson's disease; and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The company develops its products using SmartRelief, a proprietary transdermal medication delivery technology based on iontophoresis, a non-invasive method of actively transporting molecules, such as sumatriptan; and Long-Acting Delivery, a biodegradable polymer matrix, which uses medical polymers and an active drug combined to form a small implant for injection just below the skin. NuPathe Inc. was founded in 2005 and is based in Malvern, Pennsylvania. As of February 20, 2014, NuPathe, Inc. operates as a subsidiary of Teva Pharmaceutical Industries Limited.

United States and Canada
Pharmaceuticals
1.00
21.00
9.00

Investments as an LP
Medica II, Medica Venture Partners, Pitango Fund III, Pitango Venture Capital, Poalim Medica III, Sanara Ventures


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-24-2023
-
Private Placement
Buyer
Alvotech (NasdaqGM:ALVO)
Teva Pharmaceutical Industries Limited (NYSE:TEVA)

40.00
Dec-05-2022
-
Merger/Acquisition
Seller
Six brands of Teva
Karo Healthcare AB
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
11.88
Mar-22-2022
Mar-22-2022
Merger/Acquisition
Seller
Greek Manufacturing Site of Teva Pharmaceutical
Pharmapath Sarl
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
-
Oct-27-2021
-
Shelf Registration
Target
Teva Pharmaceutical Industries Limited (NYSE:TEVA)


-
Apr-23-2021
Apr-23-2021
Merger/Acquisition
Seller
Remedix
Super-Pharm (Israel) Ltd.
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-04-2023
Special Calls
Teva Pharmaceutical Industries Limited - Special Call
Oct-04-2023
Strategic Alliances
Teva Pharmaceutical Industries Limited Announces Collaboration with Sanofi to Co-Develop and Co-Develop and Co-Commercialize Teva's TEV-48574 Asset
Oct-03-2023
Company Conference Presentations
Teva Pharmaceutical Industries Limited Presents at 2023 PDA Pharmaceutical Microbiology Conference, Oct-03-2023 10:45 AM
Sep-28-2023
Executive/Board Changes - Other
Teva Announces Changes to Executive Management Team
Sep-27-2023
Company Conference Presentations
Teva Pharmaceutical Industries Limited Presents at 32nd Annual EuroFinance International Treasury Management Conference, Sep-27-2023

Competitors
3M Company (NYSE:MMM), Abbott Nutrition Manufacturing Inc., AbbVie Inc. (NYSE:ABBV), Accord Healthcare Limited, Accord Healthcare, Inc., Acerus Pharmaceuticals Corporation, Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Acura Pharmaceuticals, Inc. (OTCPK:ACUR), Adcock Ingram Holdings Limited (JSE:AIP), Adium Pharma S.A., ADVANZ PHARMA Corp. Limited, Aerie Pharmaceuticals, Inc. (Acquired), Akorn Operating Company LLC, Alcon Inc. (SWX:ALC), Alkem Laboratories Limited (NSEI:ALKEM), Alkermes plc (NasdaqGS:ALKS), Alkermes, Inc., Allergan plc, Alpha Therapeutic Corporation (Acquired), Alvogen, Inc., AMAG Pharmaceuticals, Inc., Amano Enzyme Inc., American Regent, Inc., Amneal Biosciences LLC, Amneal Pharmaceuticals Co. India Private Limited, Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), Amring Pharmaceuticals Inc., Andrx Corporation, Antares Pharma, Inc., Antibiotice S.A. (BVB:ATB), APN Outdoor Group Limited, Aptalis Pharma Canada ULC, Aspen Pharmacare Holdings Limited (JSE:APN), Astellas Pharma Ltd., AstraZeneca PLC (LSE:AZN), Auro Medics Pharma Llc, Aurobindo Pharma Limited (NSEI:AUROPHARMA), Avecho Biotechnology Limited (ASX:AVE), B. Braun Melsungen AG, Barr Laboratories, Inc., BASF Corporation, Bausch & Lomb Incorporated, Bausch Health Companies Inc. (NYSE:BHC), Bayer Aktiengesellschaft (XTRA:BAYN), Bayer Australia Limited, Bayer Pharma AG, Berlin-Chemie AG, Berlin-Chemie/Menarini Pharma Gmbh, Biofarm S.A. (BVB:BIO), Biogen MA Inc., Biotoscana Investments S.A., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals, Inc., C.H. Boehringer Sohn AG & Co. KG, Cassava Sciences, Inc. (NasdaqCM:SAVA), Cefaly Technology, Celgene Corporation, ChemoCentryx, Inc., Chiasma, Inc. (Acquired), Chiesi Farmaceutici S.p.A., Chiesi Ltd., Cipla Limited (NSEI:CIPLA), Cipla USA Inc., CJSC Gedeon Richter-RUS, Clarus Therapeutics Holdings, Inc. (Out of Business), Codexis, Inc. (NasdaqGS:CDXS), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Collegium Pharmaceutical, Inc. (NasdaqGS:COLL), Concordia Pharmaceuticals Inc., Currax Pharmaceuticals LLC, Daiichi Sankyo, Inc., Dexcel Ltd., Diocle S.p.A., DMK Pharmaceuticals Corporation (NasdaqCM:DMK), Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories Limited (BSE:500124), DSM-Firmenich AG (ENXTAM:DSFIR), Duchesnay Inc., DURECT Corporation (NasdaqCM:DRRX), Eisai Inc., Elan Corporation Limited (Acquired), electroCore, Inc. (NasdaqCM:ECOR), Eli Lilly and Company (NYSE:LLY), Elite Pharmaceuticals, Inc. (OTCPK:ELTP), EMD Serono, Inc., Emergent BioSolutions Inc. (NYSE:EBS), Endo International plc (OTCPK:ENDP.Q), Endo Pharmaceuticals Inc., eNeura Inc., Ethypharm SAS, Eurand, Inc., Eurofarma Laboratórios S.A., Fresenius Kabi USA, LLC, Fresenius SE & Co. KGaA (XTRA:FRE), Gador S.A., Generics International (US), Inc., Genmab A/S (CPSE:GMAB), Genzyme Corporation Inc, Gilead Sciences, Inc. (NasdaqGS:GILD), GP Pharm, S.A., Graybug Vision, Inc. (Acquired), GSK plc (LSE:GSK), H. Lundbeck A/S (CPSE:HLUN A), Haleon plc (LSE:HLN), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Hikma Pharmaceuticals PLC (LSE:HIK), Hikma Pharmaceuticals USA Inc., Humira S.R.O., Indivior PLC (LSE:INDV), Inspirion Delivery Sciences LLC, Intech Biopharm Corporation (TPEX:6461), Intersect ENT, Inc., Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Ipsen S.A. (ENXTPA:IPN), IVAX LLC, Janssen Pharmaceuticals, Inc., Johnson & Johnson LLC, Johnson & Johnson Private Limited, Johnson Matthey Plc (LSE:JMAT), Jubilant Pharma Limited, kaleo, Inc., King Pharmaceuticals LLC, Koninklijke Philips N.V. (ENXTAM:PHIA), Krka Farma, Ooo, KVK-TECH, Inc., KYORIN Pharmaceutical Co., Ltd. (TSE:4569), Laboratorios Bago De Bolivia Sa, Laboratorios Cinfa, S.A., Lannett Company, Inc., LANXESS Rubber N.V., Lineage Cell Therapeutics, Inc. (NYSEAM:LCTX), Lonza Group AG (SWX:LONN), Lotus Pharmaceutical Co., Ltd. (TWSE:1795), Lumara Health, Inc., Lupin Limited (BSE:500257), Lupin Pharmaceuticals, Inc., Mallinckrodt Inc. (Delaware), Mallinckrodt plc (OTCPK:MNKT.Q), Marius Pharmaceuticals, LLC, McNeil Consumer & Specialty Pharmaceuticals Inc., Medicis Pharmaceutical Corporation, Merck & Co., Inc. (NYSE:MRK), Merck (Schweiz) AG, Merck KGaA (XTRA:MRK), Merck Sharp & Dohme LLC, Mylan Technologies, Inc., Mylan Teoranta Limited, Mylan, Inc., Nanomi B.V., Neurim Pharmaceuticals (1991) Ltd., Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), Neurorecovery, Inc., Nexus Pharmaceuticals, Inc., Noramco, Inc., Novartis International AG, Novartis Pharma AG, Novartis Pharma N.V., Novartis Pharmaceuticals UK Limited, Novozymes A/S (CPSE:NZYM B), Oaklawn Park Cemetery and Funeral Home, Inc., Opiant Pharmaceuticals, Inc., OptiNose, Inc. (NasdaqGS:OPTN), Orexo US Inc, Otsuka America Pharmaceutical, Inc, Par Pharmaceutical Companies Inc., Par Pharmaceutical Holdings, Inc., Par Pharmaceutical, Inc., Penwest Pharmaceuticals Co. (Acquired), Peptron, Inc. (KOSDAQ:A087010), Perrigo Company plc (NYSE:PRGO), Perrigo Israel Pharmaceuticals Limited, Pfizer Inc. (NYSE:PFE), Plus Therapeutics, Inc. (NasdaqCM:PSTV), Prometheus Laboratories Inc., Purdue Pharma L.P., Quotient Limited, Radius Health, Inc., Rafa Laboratories Ltd., Ranbaxy Laboratories Ltd., Reading International, Inc. (NasdaqCM:RDI), Sagent Pharmaceuticals, Inc., Salvator Mundi International Hospital - Societa A Responsabilitalimitata, Sandoz Inc., Sandoz International GmbH, Sandoz S.R.L., Sanofi (ENXTPA:SAN), Sanofi Pasteur SA, Sanofi SA, Servier Laboratories Limited, Sika AG (SWX:SIKA), Somerset Pharmaceuticals, Inc., Sopharma AD (BUL:SFA), Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q), Sumitomo Pharma America, Inc., Sun Pharmaceutical Industries Inc., Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA), Sunwave Pharma Srl, Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), Takeda Pharmaceuticals International AG, Teleflex Medical Incorporated, Teligent, Inc. (Out of Business), TG Therapeutics, Inc. (NasdaqCM:TGTX), Theranica Bio-Electronics Ltd., Thermo Fisher Scientific Inc. (NYSE:TMO), Tolmar Pharmaceuticals, Inc., UCB Pharma S.A., Upjohn Inc. (Acquired), Urovant Sciences Ltd., Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA), Viatris Inc. (NasdaqGS:VTRS), Warner Chilcott plc, Watson Laboratories, Inc., Watson Pharma Private Limited, Watson Pharmaceuticals International, Ltd., Winthrop U.S., Zao Ranbaxy, Russia, Zentiva Pharma GmbH, Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521), Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702), Zydus Lifesciences Limited (NSEI:ZYDUSLIFE), Zydus Pharmaceuticals (USA) Inc.

M&A Advisors
Aklea Société d'Avocats, Barclays Bank PLC, Barclays Corporate and Investment Bank, Bear Stearns Asia Limited, Bennett Jones LLP, Blake, Cassels & Graydon LLP, Bryan Cave Leighton Paisner (Russia) LLP, Chassany Watrelot & Associés, Citigroup Inc. (NYSE:C), Clifford Chance LLP, Credit Suisse AG, Credit Suisse Securities (USA) LLC, Davies Ward Phillips & Vineberg LLP, De Brauw Blackstone Westbroek N.V., Dechert (Paris) LLP, Delfino & Associati, Dentons US LLP, Ernst & Young (Israel) Ltd., Ernst & Young LLP, Estudio Gálvez Abogados, Goldman Sachs & Co. LLC, Goldman Sachs Israel LLC, Goodwin Procter LLP, Gordon S. Blair Law Offices, Greenhill & Co., Inc. (NYSE:GHL), Israel Corporate Finance, Inc., Kesselman & Kesselman, Kinstellar, s.r.o., advokatni kancelar, Kirkland & Ellis International LLP, Kirkland & Ellis LLP, KLC Law Firm, KPMG LLP (United Kingdom), Lehman Brothers Holdings, Inc., Lehman Brothers Inc., Loyens & Loeff N.V., Morgan Stanley (NYSE:MS), Osborne Clarke LLP, Pinsent Masons, Sullivan & Cromwell LLP, Tulchinsky Stern Marciano Cohen Levitski & Co, Verusio e Cosmelli, Vinson & Elkins LLP, Willkie Farr & Gallagher LLP


Advisors
Most Recent Auditor
Kesselman & Kesselman
M&A Advisors
Aklea Société d'Avocats, Barclays Bank PLC, Barclays Corporate and Investment Bank, Bear Stearns Asia Limited, Bennett Jones LLP, Blake, Cassels & Graydon LLP, Bryan Cave Leighton Paisner (Russia) LLP, Chassany Watrelot & Associés, Citigroup Inc. (NYSE:C), Clifford Chance LLP, Credit Suisse AG, Credit Suisse Securities (USA) LLC, Davies Ward Phillips & Vineberg LLP, De Brauw Blackstone Westbroek N.V., Dechert (Paris) LLP, Delfino & Associati, Dentons US LLP, Ernst & Young (Israel) Ltd., Ernst & Young LLP, Estudio Gálvez Abogados, Goldman Sachs & Co. LLC, Goldman Sachs Israel LLC, Goodwin Procter LLP, Gordon S. Blair Law Offices, Greenhill & Co., Inc. (NYSE:GHL), Israel Corporate Finance, Inc., Kesselman & Kesselman, Kinstellar, s.r.o., advokatni kancelar, Kirkland & Ellis International LLP, Kirkland & Ellis LLP, KLC Law Firm, KPMG LLP (United Kingdom), Lehman Brothers Holdings, Inc., Lehman Brothers Inc., Loyens & Loeff N.V., Morgan Stanley (NYSE:MS), Osborne Clarke LLP, Pinsent Masons, Sullivan & Cromwell LLP, Tulchinsky Stern Marciano Cohen Levitski & Co, Verusio e Cosmelli, Vinson & Elkins LLP, Willkie Farr & Gallagher LLP
Public Offering Advisors
Kesselman & Kesselman, Tulchinsky Stern Marciano Cohen Levitski & Co, Willkie Farr & Gallagher LLP
Key development Advisor
Bear, Stearns & Co. Inc.


Most Recent Auditor
Kesselman & Kesselman


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
CFRA Equity Research
Meyer, Paige
Oct 07, 2023 04:26 PM
TEVA
Teva Pharmaceutical Industries Limited
Reports
9
GlobalData

Oct 06, 2023 06:09 AM
TEVA
Teva Pharmaceutical Industries Ltd (TEVA.XNYS) - Medical Equipment - Deals and Alliances Profile
Reports
102
GlobalData

Oct 06, 2023 01:36 AM
TEVA
Teva Pharmaceutical Industries Ltd (TEVA.TASE) - Financial and Strategic SWOT Analysis Review
Reports
470
S&P Global Compustat

Oct 05, 2023 03:30 AM
TEVA
Teva Pharmaceutical Industries Ltd 2023_10_05
Reports
17
Barclays
Prasad, Balaji V.
Oct 04, 2023 02:07 PM
TEVA
Teva Pharmaceutical Industries: TEVA-Sanofi Collaboration on Anti-TL1A Bolsters Innovation & Pivot to Growth
Reports
13
J.P. Morgan
Schott, Christopher Thomas
Oct 04, 2023 07:13 AM
TEVA
Teva Pharmaceuticals: TL1A Partnership an Incremental Positive for the Story
Notes
7
UBS Investment Bank
Verma, Ashwani
Oct 04, 2023 05:40 AM
TEVA
First Read: Teva Pharmaceuticals "TL1a divestment: timing +, proceeds ~"
Notes
14
Wright Investors' Service Inc.

Oct 03, 2023 01:34 PM
TEVA
Wright Industry Averages:  Pharmaceuticals & Biotechnology (Middle East)
Reports
50
Wright Investors' Service Inc.

Oct 03, 2023 01:34 PM
TEVA
Wright Industry Averages:  Pharmaceuticals & Biotechnology (Israel)
Reports
50
ValuEngine, Inc.

Oct 02, 2023 05:39 AM
TEVA
ValuEngine Rating and Forecast Report for TEVA
Reports
11


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Phoenix Investments & Finances Ltd

47,427,100

4.23

611.1

Jun-30-2023


BlackRock, Inc.

43,141,576

3.85

555.9

Jun-30-2023


The Vanguard Group, Inc.

36,926,506

3.30

475.8

Aug-31-2023


Ion Asset Management

33,063,004

2.95

426.0

Jun-30-2023


Clal Financial Management Ltd

31,614,669

2.82

407.3

Jun-30-2023


Migdal Mutual Funds Ltd.

30,728,330

2.74

395.9

Jun-30-2023


Menora Mivtachim Pensions & Gemel Ltd.

26,578,560

2.37

342.5

Jun-30-2023


Lingotto Investment Management LLP

24,213,261

2.16

312.0

Jun-30-2023


Rubric Capital Management LP

18,718,362

1.67

241.2

Jun-30-2023


State Street Global Advisors, Inc.

15,934,734

1.42

205.3

Sep-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Rubric Capital Management LP
18,718,362
14,218,556
Phoenix Investments & Finances Ltd
47,427,100
14,031,074
Clal Financial Management Ltd
31,614,669
12,779,003
Slate Path Capital LP
12,437,000
12,437,000
Millennium Management LLC
14,030,069
7,835,223

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Capital Research and Management Company
10,220,018
(133,830,571)
Harel Insurance Investments and Finances Services Ltd, Asset Management Arm
6,409,428
(21,194,214)
Frost Ph.D., Phillip 
0
(14,596,504)
Deutsche Asset & Wealth Management
2,634,826
(10,724,030)
Citadel Advisors LLC
4,486,045
(5,065,306)


Projects Summary
Project Name
Company Role
Project Status
Date Created
Last Updated
Deal Size($mm)
Project Raven
Target
Research
Jun-24-2020
Jul-06-2020
-


S&P Global Ratings Credit Ratings
Debt Type (Rating Type)
Current Rating
Rating Date
Current CreditWatch / Outlook
Current CreditWatch / Outlook Date
Issuer Credit Rating (Local Currency LT)
BB-
Sep-03-2020
Stable
5/31/2023 12:04:45 PM
Issuer Credit Rating (Foreign Currency LT)
BB-
Sep-03-2020
Stable
5/31/2023 12:04:45 PM


News Headlines
Date/Time
Headline
Source
Sep-15
Intas Pharma May Acquire Biosimilar Business Unit from Biogen
Marketline - Deals


Company Coverage
This company is not on any Coverage List.

Products
1% Sodium Hyaluronate Injection, Abacavir and Lamivudine Tablets, Abiraterone Acetate Tablets, Acamprosate Calcium Delayed-release Tablets, Accupril Quinapril Hydrochloride Tablets, Acitretin Capsules, Acyclovir Cream, Adapalene and Benzoyl Peroxide Gel, Adenosine injection, Adenovirus Vaccines (Future), Advicor, Aerivio Spiromax, AirDuo Digihaler, AirDuo RespiClick, Airmax, Airomir, AJOVY, Albendazole Tablets, Albutropin, Alendronate Sodium, Alfuzosin, Alpha D3, Alprostadil Injection, USP, Alvimopan Capsules, ALYQ, Amantadine HCl Tablets, Ambrisentan Tablets, Ambroxol, Amisulpride, Amlodipine and Olmesartan Medoxomil Tablets, Amlodipine Besylate & Olmesartan Medoxomil & Hydrochlorothiazide Tablets, Amphetamine Salt Tablets, Amrix, Anastrozole Tablets, Andenovirus Vaccines (Future), Antidepressant Wellbutrin XL Tablets, Apixaban Tablets, Arformoterol Tartrate Inhalation Solution, Argatroban Injection, Aripiprazole, ArmonAir DigiHaler, ArmonAir RespiClick, Arsenic Trioxide Injection (Future), Aspirin and Extended-Release Dipyridamole Capsules, Atazanavir Sulfate Capsules, Atelvia, ATL/TV1102 (Future), Atomoxetine Capsules, Atomoxetine HCl Capsules, Atorvastatin, Atorvastatin Calcium Tablets, Atractin, Attenukine, AUSTEDO, AUSTEDO XR, Autohaler, Avodart, Axert, Axiron1, Axitinib Tablets, Azacitidine Injection, Azelaic Acid Foam, Azelaic Acid Gel, Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Future), Azelastine Hydrochloride Nasal Spray (Future), AZILECT, Azithromycin, Azithromycin Suspension, Azor, Balugrastim (Future), Benazepril, Bendamustine, BENDEKA, Bicalutamide, Biosimilars (Future), Bisoprolol Fumarate and Hydrochlorothiazide Tablets, Bivalirudin for Injection, Bleomycin for Injection, Bonviva, Bosentan Tablets, Braltus, Breathe Metered Dose Inhalers, Brimonidine, Buprenorphine and Naloxone Buccal Film, Buprenorphine and Naloxone Sublingual Film (Future), Buprenorphine Transdermal System, Buprenorphine/Naloxone Sublingual Tablets, Bupropion Hydrochloride Tablets, Busulfan Injection, Cabergoline Tablets, Candesartan, Candesartan HCTZ, Carbamazepine ER Capsules, Carbidopa, Carboplatin, Cefdinir, Cefixime, Celecoxib Capsules, CellCept, CEP-32496 (Future), CEP-37247 (Future), Cetirizine Hydrochloride Tablets, CG-10639 (Future), Chlorhexidine, Ciclosporine, Cinacalcet Tablets, CINQAIR/CINQAERO, Ciprofloxacin, Cisatracurium Besylate Injection, Citalopram Oral Drops, Claravis, Clarithromycine, Clindamycin Phosphate and Benzoyl Peroxide Gel, Clonidine Transdermal System, Clopidogrel Bisulfate, Clopidogrel Hydrobromide, Clopidogrel Tablets, Clotrimazole Cream, Colchicine Tablets, Contract Manufacturing Services, Copaxone, CT-011 (Future), CT-P6, Custirsen/TV-1011 (OGX-011) (Future), Cyclobenzaprine Hydrochloride Extended-Release Capsules, Cyclohaler, Cyclosporine Pro, Dabigatran Capsules (Future), Dalfampridine ER Tablets, Dapagliflozin Tablets, Daptomycin Injection, Darunavir Tablets (Future), Debrase (Future), Deferasirox Tablets, Dermatological Hormones, Dermatological Veterinary Products, Desmopressin Acetate Injection, Desoximetasone Ointment, Desvenlafaxine Extended-Release Tablets 25, 50, & 100 Mg, Dexmedetomidine Hydrochloride Injection, Dexmethylphenidate Hydrochloride Extended-Release Capsules CII, Diacerein, Diapep-277 (Future), Diazepam, Diazepam Rectal Gel, Diclofenac Epolamine Topical Patch, Diclofenac Sodium Topical Solution, DICLOX FORTE, Diltiazem HCl, Dimethyl Fumarate Delayed-Release Capsules, Diovan, Distribution of Antadys, Distribution of Bupropion XL, Distribution of Camptosar, Distribution of Diltiazem HCl, Distribution of Estreva, Distribution Of Guaifenesin, Distribution Of Human Erythropoietin Products, Distribution of Humira (Future), Distribution of Leeloo Ge, Distribution of Lutenyl, Distribution of Monazol, Distribution of Nifedipine, Distribution of Nifedipine XL, Distribution of Orocal, Distribution Of Simvastatin, Distribution of Steri-Nebs Ampoules, Distribution of Uniretic Tablets, Divalproex ER Tablets, Docetaxel Injection, Docosanol Cream, Donepezil OD Tablets, Donepezil Tablets, Dorzolamide HCl Ophthalmic Solution, Doxazosin Mesilate, Doxepin Tablet, Doxycycline Hyclate Tablets, Doxycycline Suspension, Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets, Duloxetine DR Capsules, DuoResp, DuoResp Spiromax, Easi-Breathe (Future), Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, Effentora, Efinaconazole Topical Solution, Eletriptan HB Tablets (Future), Eletriptan Hydrobromide Tablets, Eliglustat Capsules, Eltrombopag Tablets, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, Enjuvia, Enoxaparin Sodium Injection, Entecavir Tablets, Enzalutamide Capsules, Epinephrine Injection, Epirubicin, Epirubicin Hydrochloride Injection, Epoprostenol Sodium Injection, Eporatio, Eptifibatide Injection, Erlotinib Tablets, Escitalopram Oxalate Tablets, Esomeprazole Magnesium Delayed-release Capsules, Estradiol & Norethindrone Acetate Tablets, Estradiol Vaginal Cream, Estradiol Vaginal Inserts, Estradiol Valerate and Dienogest Tablets (Future), Eszopiclone tablets, Ethinylestradiol, Etoposide Injection, Everolimus Tablets, Exemestane, Exforge, Extended Release Niacin, Ezetimibe and Atorvastatin Calcium Tablets, Ezetimibe and Simvastatin Tablets, Ezetimibe Tablets, Ezetimibe/Simvastatin Tablets, Famciclovir, Fasinumab, Fazaclo, Femara, Fenofibrate Tablets, Fentanyl Transdermal, Fexofenadine/pseudoephedrine ER tablets (Future), Finasteride, Fingolimod Capsules (Future), Flegamina, Fluconazole Suspension, Fludarabine Phosphate Injection, Fluocinolone Acetonide Topical Solution, Fluoxetine DR Capsules, Fluoxetine Tablets, Fluoxetine/olanzapine Capsules, Fluticasone Nasal Spray, Fluticasone Propionate Salmeterol Spiromax (Future), Fluticasone Propionate Spiromax, Fluticasone Salmeterol (MDI) EU, Fluticasone Salmeterol mDPI US (Future), Fluticasone Salmeterol Spiromax EU (Future), Fluvastatin Sodium Extended-release Tablets, Fosaprepitant Dimeglumine for Injection (Future), Fosaprepitant for Injection, Fosfomycin Trometamol, Fosinopril, Fremanezumab, Fulvestrant Injection, Gabapentin, Galantamine, Gemcitabine for Injection, Gemcitabine HCL (Future), Gleevec1, Gliclazide, GoResp DigiHaler (Future), Granisetron, Granisetron HCl Injection MD Vials, Granisetron HCl Injection SD Vials, GRANIX, Griseofulvin Oral Suspension, Haloperidol Decanoate Injection, HERZUMA, Hetastarch, Hydrocodone Bitartrate Extended-Release Capsules, Hydrocortisone Butyrate Cream, Hydromorphone HCL Extended-release Tablets, Hyzaar, Ibandronate, Icatibant Injection, Icosapent Capsules, Ifosfamide Injection, Imatinib Mesylate Tablets, Imiquimod Cream, Imitrex, Immunosuppressants, Indepamide, Ingenol Mebutate Gel, Integrilin, Interferon Alpha 2b, Intuniv, Ipratropium Bromide, Irbesartan, Irinotecan HCl Injection, Ivermectin Cream, Ivermectin Lotion, Ketoconazole, Lacosamide Tablets (Future), Ladostigil Tartrate (Future), Lamotrigine, Lamotrigine Extended-Release Tablets, Lansoprazole Delayed-Release Orally Disintegrating Tablets, Laquinimod, Latanoprost, LeCette (Future), Lenalidomide, Lercanidipine, Levalbuterol Tartrate HFA Inhalation Aerosol, Levetiracetam, Levocetirizine, Levodopa, Levofloxacin, Levoleucovorin Calcium for Injection, Levoleucovorin For Injection, Licensing of Ajovy, Licensing of Attenukine, Licensing of Fremanezumab, Licensing of Ninlaro, Lidocaine Transdermal Patch, Linagliptin Tablets (Future), Linezolid Tablets, Lisinopril, Lomedia 24 Fe, LONQUEX, Lorazepam, Lurasidone Hydrochloride Tablets, Macitenta Tablets, Mantadine Hydrochloride Capsules, Usp, MDT-637 (Future), Medroxyprogesterone Acetate Injectable Suspension USP, Melphalan Hydrochloride For Injection, Meropenem, Mesalamine Delayed-release Capsules, Mesalamine Delayed-Release Tablets, Mesnex, Metaxalone Tablets, Metformin Hydrochloride Extended-Release Tablets, Metformin/pioglitazone Tablets, Methotrexate Injection, Methoxsalen Capsules, Methylergonovine Maleate Tablets, Methylphenidate Extended-Release Tablets, Methylphenidate Hydrochloride Extended-Release Capsules, Methylprednisolone Acetate Injectable Suspension, USP, Metoprolol Succinate, Metoprolol Tartrate, MG01CI, Micafungin, Mifepristone Tablets, Milprosa (Future), Minocycline Hydrochloride Extended-Release Tablets, Minoxidil Topical Aerosol (Future), Mitoxantrone Hydrochloride Injection USP, Modiodal, Montelukast Sodium Oral Granules, Montelukast Sodium Tablets, Moxifloxacin HCl tablets 400 mg, Moxifloxacin Ophthalmic, Moxonidine, MultiGeneAngio (Future), Mycophenolate Mofetil, Mycophenolic Acid Delayed-Release Tablets, Myfenax, Myocet, Nafcillin, Naloxone HCl Nasal Spray, Naratriptan Tablets, NARCAN (Future), NasenDuo, Nebivolol, Neo EFG, Neugranin (Future), NexoBrid, Niaspan, Nicardipine Hydrochloride Injection, Nicardipine Injection, Nicotine Polacrilex Mini Mint Lozenges, Ninlaro, Nitrofurantoin Oral Suspension, Nomac E2 (Future), Norepinephrine Bitartrate Injection, Norethindrone Acetate and Ethinyl Estradiol Tablets and Ferrous Fumarate Tablets, Nutrilon Infant Formula, NUVIGIL, Obatoclax (Future), OGX-011/TV-1011 (Future), Olanzapine OD Tablets, OLFEN Max, Olmesartan Medoxomil and Hydrochlorothiazide Tablets, Olmesartan Medoxomil Tablets, Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets, Olmesartan medoxomil/HCTZ tablets (Future), Olopatadine Hydrochloride Ophthalmic Solutions, Omega-3-Acid Ethyl Esters, Omeprazole Magnesium Delayed-Release Tablets (Future), Oncolytics, Oral Solid-dose Products, Orlistat, Ortho Tri-Cyclen Lo, Oseltamivir Phosphate, Oxaliplatin Injection, Oxcarbazapine, Oxcarbazapine Hydrochloride Tablets, Oxcarbazepine Tablets, Oxcodone Hydrochloride and Acetaminophen Extended-Release Tablets, Oxybutynin vaginal ring (Future), OxyContin, Oxymorphone Tablets, Pagoclone (Future), Palonosetron Hydrochloride Injection, Palonosetron IV Solution, Pantoprazole, Paricalcitol Capsules, Paricalcitol Injection (Future), Paroxetin, PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid, Pemetrexed Disodium Injection, Pemetrexed Disodium Injection PDR Inf Vial, Penicillamine Capsules, Perampanel Tablets, Perindopril, Perphenazine Tablets, Phenylephrine, Pimecrolimus Cream, Pioglitazone-hydrochloride Tablets, Piperacillin, Pirfenidone Tablets, Polyethylene Glycol 3350 NF, PolyHeal (Future), Pralatrexate Injection, Pravastatin, Prednisolone Enteric-coated Tablets, Pregabalin Capsules, Prevacid, Pridopidine, ProAir Digihaler, ProAir e-RespiClick, ProAir HFA, ProAir Hydrofluoroalkane, ProAir mDPI US (Future), ProAir RespiClick, Progesterone Capsules, Progesterone Soft Gel Capsules, Propofol Injectable Emulsion, Pseudoephedrine Hydrochloride Tablets, QNASL, QNAZE (Future), Quartette, Quetiapine Fumarate, Quetiapine Tablets, Quinine Sulfate Capsules, QVAR, QVAR BAI US (Future), QVAR RediHaler, Rabeprazole Sodium Delayed-Release Tablets, RAJANI, Raloxifene, Raloxifine Tablets (Future), Ramelteon Tablets, Ramipril, Ranivisio, Ranolazine Extended-Release Tablets, Rasagiline Tablets, Ratiograstim, Ribavirin, Rifaximin, Rilmenidine, Risedronate Sodium Tablets, Risedronic Acid, Risperidone LAI (Future), Rivastigmine Tartrate, Rivelsa Tablets, Rizatriptan Benzoate, Rizatriptan Tablets (Future), Rocuronium Bromide Injection, Romidepsin, Rosiglitazone Maleate (Future), Rosiglitazone Maleate/ Glimepiride, Rosuvastatin Tablets, Rotigotine Transdermal System, Sales of Adasuve, Saxagliptin Tablets, Seroquel Tablets, Sibutramine, Sildenafil, Sildenafil Citrate, Solifenacin Succinate Tablets, Sorafenib Tablets, Spasfon, Spiromax, StemEx (Future), Steri-Neb, Suboxone, SUDOCREM, Sulfamethoxazole and Trimethoprim injection, Sumatriptan Injection, Sumatriptan Succinate Injection, Sumatriptan Succinate Tablets, Sustiva, Synribo, Syprine 1, Tacni, Tadalafil, Talampanel (Future), Tamsulosin Capsules (Future), Tamsulosin Hydrochloride Capsules, Tamulosin HCl Capsules, Telmisartan, Temazepam, Temodar, Temozolamide Capsules, Tenofovir Disoproxil Fumarate Tablets, Terbinafine Hydrochloride Tablets, Teriparatide (Future), Testosterone Gel, Testosterone Topical Solution CIII, TEV-48125 (Future), TEV-48574 (Future), TEV-53275, TEV-90110, TEV-90111, TEV-90112, TEV-90113, TEV-TROPIN, TEV-TROPINR, Tevas Meloxicam Tablets, Tiagabine Hydrochloride Tablets, Ticagrelor Tablets, Tidal Inhaler (Future), Tjet, TOBI, Tobramycin Inhalation Solution, Tobramycin Injection, Tolterodine Tartrate ER, Topiramate, Topotecan Injection, Trandolapril, TREANDA, Treprostinil Injection, Tri-Lo Sprintec Tablets, Triamcinolone Acetonide Injectable Suspension, Trientine Hydrochloride Capsules, Triflusal, Trileptal, TRISENOX, Truxima, TV-44649 (Future), TV-44664 (Future), TV-45070, TV-45070 Topical (Future), TV-46000 (Future), Ursodiol, UZEDY, Valaciclovir, Valacyclovir Tablets, Valganciclovir Hydrochloride Oral Solution, Vardenafil Hydrochloride Tablets, Varenicline Tablets, Vecuronium Bromide for Injection, Venlafaxine, Venlafaxine HCl, Venlaflaxide, Ventolin HFA, Vigabatrin, Vilazodone HCl Tablets, Vogalene, Vogalib, Voriconazole Tablets, VX15 (Future), Xeloda, XM17 (Future), XM22 (Future), Zaleplon Capsules, Zecuity, Zetia, Zofran, Zoledronic Acid Injection, Zolpidem


Upcoming Events
Date/Time
Type
Oct-16-2023
Company Conference Presentations
Oct-16-2023
Conferences
Nov-01-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-04-2023
Oct-04-2023
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
SEC
8-K (7.01, 9.01)
188 KB
Sep-28-2023
Sep-25-2023
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
SEC
8-K (5.02, 7.01, 9.01)
168 KB
Aug-24-2023
Aug-21-2023
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
SEC
8-K (1.01, 7.01, 9.01)
255 KB
Aug-02-2023
Aug-01-2023
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
SEC
8-K (5.02)
142 KB
Aug-02-2023
Jun-30-2023
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
SEC
10-Q
14 MB
Aug-02-2023
Aug-02-2023
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
SEC
8-K (2.02, 9.01)
1 MB
Jun-15-2023
Jun-15-2023
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
SEC
8-K (5.07)
150 KB
Jun-08-2023
Jun-08-2023
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
SEC
8-K (1.01, 7.01, 9.01)
189 KB
May-24-2023
-
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
SEC
DEFA14A
15 KB
May-11-2023
May-08-2023
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
SEC
8-K (5.02)
140 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Kalif, Eliyahu Sharon (Executive VP & CFO)
Aug-07-2023
Ordinary Shares
(35,125)
(465,875)
Private Disposition
(26.16)
Form 4
Barer Ph.D., Sol J. (Independent Chairman of the Board)
Aug-04-2023
Ordinary Shares
28,162
0
Derivative Exercise and Retained Stock
8.20
Form 4
Elstein, Amir  (Independent Director)
Aug-04-2023
Ordinary Shares
15,810
0
Derivative Exercise and Retained Stock
0.77
Form 4
Lieberman B.sc (Hons), CPA, Gerald M. (Independent Director)
Aug-04-2023
Ordinary Shares
15,810
0
Derivative Exercise and Retained Stock
22.88
Form 4
Mignone, Roberto Agostino (Independent Director)
Aug-04-2023
Ordinary Shares
15,810
0
Derivative Exercise and Retained Stock
26.90
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Barer, Sol J.
Independent Chairman of the Board
972 3 914 8213
-

Francis, Richard D.
President, CEO & Director
972 3 914 8213
-

Crane, Rosemary A.
Independent Director
972 3 914 8213
-

Elstein, Amir 
Independent Director
972 3 914 8213
-
amir.elstein@intel.com
Lieberman, Gerald M.
Independent Director
(917) 684-1558
-
jerrylieberman18@gmail.com
Mignone, Roberto Agostino
Independent Director
972 3 914 8213
-
-
Vergis, Janet S.
Independent Director
972 3 914 8213
-

Braverman-Blumenstyk, Michal 
Nominee Independent Director
972 3 914 8213
-

Nisen, Perry D.
Independent Director
(858) 551-4880
-
perry@sofinnova.com
Satchi-Fainaro, Ronit 
Independent Director
972 3 914 8213
-

Shalev, Varda 
Independent Director
972 3 914 8213
-

Zaks, Tal 
Independent Director
972 3 914 8213
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Francis, Richard D.
President, CEO & Director
972 3 914 8213
-

Kalif, Eliyahu Sharon
Executive VP & CFO
972 3 914 8213
-

Drape, Eric 
Executive Vice President of Global Operations
972 3 914 8213
-

Weiss, Amir 
Senior VP & Chief Accounting Officer
972 3 914 8213
-

Meir, Ran 
Head of Investor Relations
+1 (267) 468-4475
-

Stark, David M.
Executive VP & Chief Legal Officer
972 3 914 8213
-

Veit, Kathleen 
Senior Vice President, Global Compliance & Ethics Officer
972 3 914 8213
-

Inbar, Galia 
Executive VP, Chief Human Resources Officer & Corporate Affairs
972 3 914 8213
-

Baron, Nir 
Senior VP & Chief Internal Auditor
972 3 914 8213
-
-
Daniell, Richard Gordon
Executive Vice President of European Commercial
972 3 914 8213
-

Dethlefs, Sven 
Executive Vice President of North America Commercial
972 3 914 8213
-

Grant, Angus J.
Executive Vice President of Business Development
972 3 914 8213
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
